<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01720108</url>
  </required_header>
  <id_info>
    <org_study_id>EPCATII.001</org_study_id>
    <nct_id>NCT01720108</nct_id>
  </id_info>
  <brief_title>Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty</brief_title>
  <acronym>EPCAT II</acronym>
  <official_title>Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David Anderson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nova Scotia Health Authority</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the investigators want to look at whether using aspirin instead of rivaroxaban&#xD;
      (after initial treatment with rivaroxaban) works as well at preventing blood clots while also&#xD;
      reducing risk of bleeding and is more cost effective in patients who have either a total hip&#xD;
      replacement or total knee replacement.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 24, 2013</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>symptomatic venous thromboembolism</measure>
    <time_frame>up to 4 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>major or clinically relevant non-major bleeding</measure>
    <time_frame>up to 4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>survival</measure>
    <time_frame>up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>myocardial infarction</measure>
    <time_frame>up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stroke</measure>
    <time_frame>up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>wound infection</measure>
    <time_frame>up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cost-effectiveness</measure>
    <time_frame>up to 4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3426</enrollment>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>rivaroxaban</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>rivaroxaban 10mg x 9 days for total knee arthroplasty patients; x 30 days for total hip athroplasty patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASA 81mg x 9 days for total knee arthroplasty patients; x 30 days for total hip athroplasty patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rivaroxaban and ASA</intervention_name>
    <arm_group_label>ASA</arm_group_label>
    <arm_group_label>rivaroxaban</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. All patients undergoing elective total hip or knee arthroplasty at the participating&#xD;
        institutions will be potentially eligible for this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hip or lower limb fracture in the previous three months&#xD;
&#xD;
          2. Metastatic cancer&#xD;
&#xD;
          3. Life expectancy less than 6 months&#xD;
&#xD;
          4. History of major bleeding that in the judgment of the investigator precludes use of&#xD;
             anticoagulant prophylaxis&#xD;
&#xD;
          5. History of aspirin allergy, active peptic ulcer disease or gastritis that in judgment&#xD;
             of investigator precludes use of aspirin&#xD;
&#xD;
          6. History of significant hepatic disease or any other condition that in the judgement of&#xD;
             the investigator precludes the use of rivaroxaban&#xD;
&#xD;
          7. Creatinine clearance less than 30 ml per minute&#xD;
&#xD;
          8. Platelet count less than 100 x 109 /L&#xD;
&#xD;
          9. Need for long-term anticoagulation due to a preexisting co-morbid condition or due to&#xD;
             the development of venous thromboembolism following surgery but prior to randomization&#xD;
&#xD;
         10. Did not or will not receive rivaroxaban post-operatively for VTE prophylaxis&#xD;
&#xD;
         11. Bilateral total hip arthroplasty or simultaneous hip and knee arthroplasty&#xD;
&#xD;
         12. Major surgical procedure within the previous three months&#xD;
&#xD;
         13. Requirement for major surgery post arthroplasty within 90 day period&#xD;
&#xD;
         14. Chronic daily aspirin use with dose greater than 100 mg a day&#xD;
&#xD;
         15. Women of child bearing potential who are not abstinent or do not use appropriate&#xD;
             contraception throughout the study drug period&#xD;
&#xD;
         16. Geographical inaccessibility for follow-up&#xD;
&#xD;
         17. Unwilling or unable to give consent&#xD;
&#xD;
         18. Previous participation in the study&#xD;
&#xD;
         19. Concomitant use with drugs that are strong inhibitors or inducers of both P-gp and&#xD;
             CYP3A4&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David R Anderson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nova Scotia Health Authority</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Capital Health</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>October 30, 2012</study_first_submitted>
  <study_first_submitted_qc>October 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2012</study_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nova Scotia Health Authority</investigator_affiliation>
    <investigator_full_name>David Anderson</investigator_full_name>
    <investigator_title>Head, Department of Medicine, CDHA</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

